OncLive SOSS

Post-Conference Perspectives: Recent Advances in the Management of Chronic GvHD - Episode 6

Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients

August 2, 2023

Preet M. Chaudhary, MD, PhD, Noah Merin, MD, PhD

A brief review of the key efficacy data for two treatment options, Ibrutinib and Belumosudil, in patients with chronic GvHD.

EP. 1: The Chronic GvHD Landscape: Risk Factors and Diagnosis

EP. 2: First-line Treatment for Patients with Chronic GvHD

EP. 3: Defining and Managing Steroid Refractory Chronic GvHD

EP. 4: Role of Ruxolitinib in Steroid-Refractory Chronic GvHD

EP. 5: Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil

EP. 6: Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients

EP. 7: Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD

EP. 8: Future Directions in Chronic GvHD